Myocarditis in Patients Treated With Immune Checkpoint InhibitorsSyed Mahmood, Tomas G. Neilan, Sarju Ganatra et al.|Journal of the American College of Cardiology|2018Cited by 1.5k
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology SocietyAlexander R. Lyon, Teresa López‐Fernández, Daniel J. Lenihan et al.|European Journal of Heart Failure|2020Cited by 767
Timing and Causes of Readmission After Acute Heart Failure Hospitalization—Insights From the Heart Failure Network TrialsJustin Vader, Lisa de las Fuentes, Shane LaRue et al.|Journal of Cardiac Failure|2016Cited by 99
Plasma Metabolomics Identifies Signatures that Distinguish Heart Failure with Reduced and Preserved Ejection FractionFawaz Naeem, Daniel P. Kelly, Teresa C. Leone et al.|ESC Heart Failure|2025Cited by 12
Targeted Quantitative Plasma Metabolomics Identifies Metabolite Signatures that Distinguish Heart Failure with Reduced and Preserved Ejection FractionFawaz Naeem, Daniel P. Kelly, Teresa C. Leone et al.|medRxiv|2024Cited by 2